This test can identify the severity and prognosis, in triaging of hospitalised COVID-19 patients, and helps to determine if a patient might require IMV (Intubation with Mechanical Ventilation) and ICU facility. The test is available in India for INR 4500 and the TAT is within 6 hours of receiving the sample.
According to reports, every time there is a spike in COVID-19 cases, the number of beds in hospitals and especially the ICU beds fall short in almost all major cities despite all advance preparations. Especially the recent second wave has overwhelmed the healthcare system, leaving hospitals struggling to cope with the shortage of critical drugs, oxygen cylinders, and ICU beds. Hence, the urgent need of the hour was to focus on enhancing patient care while prioritizing hospital resources.
In individuals with severe clinical courses, the disease often manifests in two waves. In the first, the patient has typical clinical symptoms of respiratory tract infection, and after 8–12 days, the second wave starts with sudden worsening of respiratory status. Diffuse ground-glass opacities on CT, lymphopenia, elevated D-dimer levels, and prolonged prothrombin time are common laboratory abnormalities in these critically ill patients. Although documented in all ages, the mortality rate is particularly high among the elderly and those with pre-existing co-morbidities (such as diabetes, hypertension, and chronic lung disease). Increased levels of interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) have been documented in severely infected individuals.
Speaking about the test launch, Ameera Shah, Promoter and Managing Director of Metropolis Healthcare Ltd. said, “We are glad to launch the CoviRisk TBNK test just in time before the 3rd wave. As no one is aware of the extent of uncertainties India could face, the need of the hour is early recognition of the right course of action for hospitalised COVID-19 patients which can help in making the right treatment choice for patients while prioritizing precious resources.”
Multiple studies and evidence suggest that Flow Cytometry data can be used to explore the role of T-Cell subtypes as a surrogate biomarker to risk, disease severity, and clinical outcomes for patients suffering from COVID-19. CoviRisk TBNK by Flowcytometry can be one of such biomarkers.
Dr. Kirti Chadha, Group Head Medical Affairs at Metropolis Healthcare Ltd, said, “CD4 and CD8 T cells are important for triggering an immune response to bacterial and viral infections. In COVID-19 patients, the CD4 and CD8 T cell counts typically decrease with increasing severity of the disease and can help assess the immune response of COVID-19 patients. The dysregulation of these immune parameters, along with bacterial coinfection are important causes of exacerbation of the patients’ condition and death.”
Commenting on the new diagnostics test , Dr. Sanjay Gohil, MD (Path) Consultant Pathologist Head of Dept. Haematology & Transplant Immunology (HLA) Metropolis Healthcare Ltd. said, “The new test could provide the much-needed assurance to the patients and will help reduce the stress on our healthcare infrastructure as well as medical professionals by helping them identify the level of risk and accordingly take the next steps.”